日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Phase 3b Extension Study MT-1186-A04 to Evaluate the Continued Efficacy and Safety of Edaravone Oral Suspension for Up to an Additional 48 Weeks in Patients With Amyotrophic Lateral Sclerosis

MT-1186-A04 3b 期扩展研究旨在评估依达拉奉口服混悬液在肌萎缩侧索硬化症患者中持续 48 周的疗效和安全性

期刊:Muscle & Nerve
影响因子:3.1
doi:10.1002/mus.70120
Genge, Angela; Rothstein, Jeffrey; De Silva, Shari; Zinman, Lorne; Chum, Marvin; Chiò, Adriano; Sobue, Gen; Aoki, Masashi; Yoshino, Hiide; Doyu, Manabu; Selness, Daniel; Todorovic, Vesna; Hirai, Manabu; Sasson, Nissim; Takahashi, Fumihiro; Cecić, Michelle; Wamil, Art; Apple, Stephen
发表日期：2026
文献求助 收藏

Efficacy and Safety of Once Daily Dosing vs. Approved On/Off Dosing of Edaravone Oral Suspension Up to 48 Weeks in Patients With Amyotrophic Lateral Sclerosis (Study MT-1186-A02)

肌萎缩侧索硬化症患者每日一次给药与批准的间歇性给药方案（依达拉奉口服混悬液）长达 48 周的疗效和安全性比较（MT-1186-A02 研究）

期刊:Muscle & Nerve
影响因子:3.1
doi:10.1002/mus.28448
Rothstein, Jeffrey; Genge, Angela; De Silva, Shari; Zinman, Lorne; Chum, Marvin; Chio, Adriano; Sobue, Gen; Aoki, Masashi; Yoshino, Hiide; Doyu, Manabu; Selness, Daniel; Todorovic, Vesna; Sasson, Nissim; Hirai, Manabu; Takahashi, Fumihiro; Salah, Alejandro; Wamil, Art; Apple, Stephen
发表日期：2025
文献求助 收藏

Safety Extension Study of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis for up to an Additional 96 Weeks of Treatment

一项针对肌萎缩侧索硬化症患者的依达拉奉口服混悬液安全性扩展研究，疗程最长可达96周

期刊:Muscle & Nerve
影响因子:3.1
doi:10.1002/mus.28451
Genge, Angela; Pattee, Gary L; Sobue, Gen; Aoki, Masashi; Yoshino, Hiide; Couratier, Philippe; Lunetta, Christian; Petri, Susanne; Selness, Daniel; Todorovic, Vesna; Sasson, Nissim; Hirai, Manabu; Takahashi, Fumihiro; Salah, Alejandro; Apple, Stephen; Wamil, Art; Kalin, Alexander; Jackson, Carlayne E
发表日期：2025
文献求助 收藏

Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment

口服依达拉奉在肌萎缩侧索硬化症患者中经过 48 周治疗后显示出良好的安全性。

期刊:Muscle & Nerve
影响因子:3.1
doi:10.1002/mus.27768
Genge, Angela; Pattee, Gary L; Sobue, Gen; Aoki, Masashi; Yoshino, Hiide; Couratier, Philippe; Lunetta, Christian; Petri, Susanne; Selness, Daniel; Bidani, Sachin; Hirai, Manabu; Sakata, Takeshi; Salah, Alejandro; Apple, Stephen; Wamil, Art; Kalin, Alexander; Jackson, Carlayne E
发表日期：2023
文献求助 收藏

Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration

肌萎缩侧索硬化症患者氧化应激增加及依达拉奉给药的影响

期刊:Redox Report
影响因子:7.4
doi:10.1179/1351000215Y.0000000026
Nagase, Midori; Yamamoto, Yorihiro; Miyazaki, Yusuke; Yoshino, Hiide
毒理研究
氧化应激
发表日期：2016
文献求助 收藏

Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients

一项旨在验证依达拉奉（MCI-186）治疗肌萎缩侧索硬化症患者疗效和安全性的双盲、平行组、安慰剂对照研究

期刊:Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
影响因子:2.8
doi:10.3109/21678421.2014.959024
Abe, Koji; Itoyama, Yasuto; Sobue, Gen; Tsuji, Shoji; Aoki, Masashi; Doyu, Manabu; Hamada, Chikuma; Kondo, Kazuoki; Yoneoka, Takatomo; Akimoto, Makoto; Yoshino, Hiide
发表日期：2014
文献求助 收藏

The TRK-fused gene is mutated in hereditary motor and sensory neuropathy with proximal dominant involvement

TRK融合基因突变与近端显性遗传性运动感觉神经病相关。

期刊:American Journal of Human Genetics
影响因子:8.1
doi:10.1016/j.ajhg.2012.07.014
Ishiura, Hiroyuki; Sako, Wataru; Yoshida, Mari; Kawarai, Toshitaka; Tanabe, Osamu; Goto, Jun; Takahashi, Yuji; Date, Hidetoshi; Mitsui, Jun; Ahsan, Budrul; Ichikawa, Yaeko; Iwata, Atsushi; Yoshino, Hiide; Izumi, Yuishin; Fujita, Koji; Maeda, Kouji; Goto, Satoshi; Koizumi, Hidetaka; Morigaki, Ryoma; Ikemura, Masako; Yamauchi, Naoko; Murayama, Shigeo; Nicholson, Garth A; Ito, Hidefumi; Sobue, Gen; Nakagawa, Masanori; Kaji, Ryuji; Tsuji, Shoji
发表日期：2012
文献求助 收藏